Biopharmaceuticals Market Research Report Information By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins) and Application (Oncology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases) – Forecast to 2032

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE

6.1. Overview

6.2. Monoclonal Antibodies

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.3. Recombinant Growth Factors

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.3.1. Erythropoietin

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.3.2. Granulocyte Colony Stimulating Factor

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.4. Purified Proteins

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.4.1. Leukemia Inhibitory Factor (LIF)

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.4.2. P53 Protein

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.4.3. P38 Protein

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.4.4. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5. Recombinant Proteins

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5.1. Serum Albumin

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5.2. Amyloid Protein

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5.3. Defensin

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5.4. Transferrin

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.5.5. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.6. Recombinant Hormones

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7. Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1. Recombinant Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.1. Cancer Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.2. Malaria Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.3. Ebola Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.4. Hepatitis B Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.5. Tetanus Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.6. Diptheria Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.7. Cholera Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.1.8. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.2. Conventional Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.2.1. Polio Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.2.2. Pox Vaccines

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.2.3. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.7.3. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.8. Synthetic Immunomodulators

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.8.1. Cytokines, Interferones, Interleukins

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.8.2. Tumor Necrosis Factor (TNF)

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.8.3. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

6.9. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7. GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION

7.1. Overview

7.2. Oncology

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.3. Inflammatory and Infectious Diseases

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.4. Autoimmune Disorders

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.5. Metabolic Disorders

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.6. Hormonal Disorders

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.7. Disease Prevention

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.8. Cardiovascular Diseases

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.9. Neurological Diseases

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

7.10. Others

Market Estimates & Forecast, by Region, 2019–2027

Market Estimates & Forecast, by Country, 2019–2027

8. GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. North America

8.2.1.1. US

8.2.1.2. Canada

8.2.2. Latin America

8.3. Europe

8.3.1. Western Europe

8.3.1.1. Germany

8.3.1.2. France

8.3.1.3. Italy

8.3.1.4. Spain

8.3.1.5. UK

8.3.1.6. Rest of Western Europe

8.3.2. Eastern Europe

8.4. Asia-Pacific

8.4.1. Japan

8.4.2. China

8.4.3. India

8.4.4. Australia

8.4.5. South Korea

8.4.6. Rest of Asia-Pacific

8.5. Middle East & Africa

8.5.1. Middle East

8.5.2. Africa

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Biopharmaceuticals Market

9.5. Competitive Benchmarking

9.6. Leading Players in terms of Number of Developments in the Global Biopharmaceuticals Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2019

9.8.2. Major Players R&D Expenditure 2019

9.9. Major Players Capital Market Ratio

10. COMPANY PROFILES

10.1. Pfizer, Inc.

10.1.1. Company Overview

10.1.2. Product Overview

10.1.3. Financial Overview

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Amgen Inc.

10.2.1. Company Overview

10.2.2. Product Overview

10.2.3. Financial Overview

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Eli Lilly and Company

10.3.1. Company Overview

10.3.2. Product Overview

10.3.3. Financial Overview

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. F. Hoffmann-La Roche Ltd

10.4.1. Company Overview

10.4.2. Product Overview

10.4.3. Financial Overview

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Johnson & Johnson

10.5.1. Company Overview

10.5.2. Product Overview

10.5.3. Financial Overview

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Gilead Sciences, Inc.

10.6.1. Company Overview

10.6.2. Product Overview

10.6.3. Financial Overview

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. AstraZeneca

10.7.1. Company Overview

10.7.2. Product Overview

10.7.3. Financial Overview

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Abbvie Inc.

10.8.1. Company Overview

10.8.2. Product Overview

10.8.3. Financial Overview

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Sanofi

10.9.1. Company Overview

10.9.2. Product Overview

10.9.3. Financial Overview

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Bristol-Myers Squibb Company

10.10.1. Company Overview

10.10.2. Product Overview

10.10.3. Financial Overview

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Sandoz International GmbH

10.11.1. Company Overview

10.11.2. Product Overview

10.11.3. Financial Overview

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Novo Nordisk A/S

10.12.1. Company Overview

10.12.2. Product Overview

10.12.3. Financial Overview

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

10.13. GlaxoSmithKline PLC

10.13.1. Company Overview

10.13.2. Product Overview

10.13.3. Financial Overview

10.13.4. Key Developments

10.13.5. SWOT Analysis

10.13.6. Key Strategies

10.14. Merck KGaA

10.14.1. Company Overview

10.14.2. Product Overview

10.14.3. Financial Overview

10.14.4. Key Developments

10.14.5. SWOT Analysis

10.14.6. Key Strategies

10.15. Biocon

10.15.1. Company Overview

10.15.2. Product Overview

10.15.3. Financial Overview

10.15.4. Key Developments

10.15.5. SWOT Analysis

10.15.6. Key Strategies

10.16. Others

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL BIOPHARMACEUTICALS MARKET SYNOPSIS, 2019–2027

TABLE 2 GLOBAL BIOPHARMACEUTICALS MARKET ESTIMATES & FORECAST, 2019–2027 (USD MILLION)

TABLE 3 GLOBAL BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 4 GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 5 GLOBAL BIOPHARMACEUTICALS MARKET, BY REGION, 2019–2027 (USD MILLION)

TABLE 6 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 8 US: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 9 US: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 10 CANADA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 11 CANADA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 12 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 13 LATIN AMERICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 14 EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 15 EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 16 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 17 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 18 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 19 EASTERN EUROPE: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2019–2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2019–2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOPHARMACEUTICALS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOPHARMACEUTICALS MARKET

FIGURE 4 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY PRODUCT TYPE, 2019 (%)

FIGURE 5 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY APPLICATION, 2019 (%)

FIGURE 6 GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 7 AMERICAS: BIOPHARMACEUTICALS MARKET SHARE BY REGION, 2019 (%)

FIGURE 7 NORTH AMERICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 8 EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 9 WESTERN EUROPE: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 10 ASIA-PACIFIC: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 11 MIDDLE EAST & AFRICA: BIOPHARMACEUTICALS MARKET SHARE, BY COUNTRY, 2019 (%)

FIGURE 12 GLOBAL BIOPHARMACEUTICALS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)

FIGURE 13 PFIZER, INC..: KEY FINANCIALS

FIGURE 14 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 15 PFIZER, INC.: REGIONAL REVENUE

FIGURE 16 AMGEN INC.: KEY FINANCIALS

FIGURE 17 AMGEN INC.: SEGMENTAL REVENUE

FIGURE 18 AMGEN INC.: REGIONAL REVENUE

FIGURE 19 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 20 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 21 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 22 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS

FIGURE 23 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE

FIGURE 24 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE

FIGURE 25 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 26 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 27 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 28 GILEAD SCIENCES, INC.: KEY FINANCIALS

FIGURE 29 GILEAD SCIENCES, INC.: SEGMENTAL REVENUE

FIGURE 30 GILEAD SCIENCES, INC.: REGIONAL REVENUE

FIGURE 31 ASTRAZENECA: KEY FINANCIALS

FIGURE 32 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 33 ASTRAZENECA: REGIONAL REVENUE

FIGURE 34 ABBVIE INC.: KEY FINANCIALS

FIGURE 35 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 36 ABBVIE INC.: REGIONAL REVENUE

FIGURE 37 SANOFI: KEY FINANCIALS

FIGURE 38 SANOFI: SEGMENTAL REVENUE

FIGURE 39 SANOFI: REGIONAL REVENUE

FIGURE 40 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS

FIGURE 41 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE

FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE

FIGURE 43 SANDOZ INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 44 SANDOZ INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 45 SANDOZ INTERNATIONAL GMBH: REGIONAL REVENUE

FIGURE 46 NOVO NORDISK A/S: KEY FINANCIALS

FIGURE 47 NOVO NORDISK A/S: SEGMENTAL REVENUE

FIGURE 48 NOVO NORDISK A/S: REGIONAL REVENUE

FIGURE 49 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 50 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 51 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 52 MERCK KGAA: KEY FINANCIALS

FIGURE 53 MERCK KGAA: SEGMENTAL REVENUE

FIGURE 54 MERCK KGAA: REGIONAL REVENUE

FIGURE 55 BIOCON: KEY FINANCIALS

FIGURE 56 BIOCON: SEGMENTAL REVENUE

FIGURE 57 BIOCON: REGIONAL REVENUE